true

Avitene™ Microfibrillar Collagen Hemostat

Microfibrillar Collagen Hemostat Flour

Overview
Highlights
Products & Accessories
EIFU & Resources
FAQs

Standardize on the proven solution for active hemostasis.

Avitene™ Microfibrillar Collagen Hemostat is an active absorbable collagen hemostat, proven to accelerate clot formation. Avitene™ effectively enhances platelet aggregation and the release of proteins to form fibrin, resulting in hemostasis.

true

AVITENE™ FLOUR

Effective in controlling arterial bleeding
Conforms and adheres to irregular spaces
Easy removal with irrigation and suction

AVITENE™ SHEETS

Cut to any shape or size
Ideal for flat surfaces or to wrap vessels and anastomosis sites

Learn More

AVITENE™ ULTRAFOAM™ COLLAGEN SPONGE

Easy, effective solution for hemostasis
In an animal study, UltraFoam™ Collagen without thrombin was as effective as Gelfoam^® Sponge with thrombin
Reduced thrombin usage may lower cost
Soft, pliable sponge is ready-to-use out of the package
No soaking necessary

Learn More

MULTIPLE FORMS FOR EVERY SPECIALTY:

The proven solution for controlling bleeding in all surgical applications, including neurosurgery
Trusted by surgeons for its safety and efficacy for over 40 years

Indications:

Avitene™ Microfibrillar Collagen Hemostat (MCH) and Avitene™ UltraFoam™ sponge are indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

Contraindications:

Avitene™ MCH and Avitene™ UltraFoam™ sponge should not be used in the closure of skin incisions as they may interfere with the healing of the skin edges. This is due to simple mechanical interposition of dry collagen and not to any intrinsic interference with wound healing.
It has been reported with other collagen hemostatic agents, that by filling porosities of cancellous bone, they may significantly reduce the bond strength of methylmethacrylate adhesives. Avitene™ MCH and Avitene™ UltraFoam™ sponge should not, therefore, be employed on bone surfaces to which prosthetic materials are to be attached with methylmethacrylate adhesives.

Warnings:

Avitene™ MCH and Avitene™ UltraFoam™ are inactivated by autoclaving.
Ethylene oxide reacts with bound hydrochloric acid to form ethylene chlorohydrin.
These devices have been designed for single use only. Reuse, reprocessing, resterilization or repackaging may compromise the structural integrity and/or essential material and design characteristics that are critical to the overall performance of the devices and may lead to device failure which may result in injury to the patient. Reuse, reprocessing, resterilization or repackaging may also create a risk of contamination of the device and/or cause patient infection or cross infection, including, but not limited to, the transmission of infectious diseases from one patient to another. Contamination of the devices may lead to injury, illness or death of the patient or end user. Opened, unused product should be discarded.
Moistening Avitene™ MCH or wetting with saline or thrombin impairs its hemostatic efficacy. It should be used dry.
As with any foreign substance, use of Avitene™ MCH and Avitene™ UltraFoam™ in contaminated wounds may enhance infection.
Avitene™ UltraFoam™ sponge should not be used in instances of pumping arterial hemorrhage.
Avitene™ UltraFoam™ should not be used where blood or other fluids have pooled, or in cases where the point of hemorrhage is submerged as it may mask an underlying source of bleeding, resulting in hematoma.
Avitene™ UltraFoam™ sponge will not act as a tampon or plug in a bleeding site, nor will it close off an area of blood collecting behind a tampon.
Avitene™ UltraFoam™ sponge is not intended to treat systemic coagulation disorders.
Avitene™ MCH and Avitene™ UltraFoam™ are not for injection, intraocular or intravascular use.

Adverse Reactions:

The most serious adverse reaction reported which may be related to the use of Avitene™ MCH or other collagen products are potentiation of infection including abscess formation, hematoma, wound dehiscence and mediastinitis.
Other reported adverse reactions possibly related are adhesion formation, allergic reaction, foreign body reaction and subgaleal seroma (report of a single case) and increased incidence of alveolalgia when used for packing of dental extraction sockets.
Transient laryngospasm due to aspiration of dry material has been reported following use of Avitene™ MCH in tonsillectomy.

Please consult package insert for more detailed safety information and instructions for use.

Hemostatic Agents and How They are Used

Hemostatic agents are substances to help prevent/stop bleeding from the bleeding site and involves the dependent reactions of plasma proteins, calcium ions and blood platelets which softens the platelet plug from the fibrinogen-to-fibrin conversion.

Learn more

Controlling Surgical Bleeding

Overview of Surgical Bleeding

Learn more

1 Arista™ AH PMA P050038 Clinical Study.
2 See full Instructions for Use for detailed application instructions.
3 Arista™ AH Instructions for Use.

INDICATIONS

Arista™ AH is indicated in surgical procedures (except neurological and ophthalmic) as an adjunctive hemostatic device to assist when control of capillary, venous, and arteriolar bleeding by pressure, ligature, and other conventional procedures are ineffective or impractical.

CONTRAINDICATIONS

Do not inject or place Arista™ AH into blood vessels as potential for embolization and death may exist.

WARNINGS

Arista™ AH is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis.

Once hemostasis is achieved, excess Arista™ AH should be removed from the site of application by irrigation and aspiration particularly when used in and around foramina of bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm. Arista™ AH swells to its maximum volume immediately upon contact with blood or other fluids. Dry, white Arista™ AH should be removed. The possibility of the product interfering with normal function and/or causing compression necrosis of surrounding tissues due to swelling is reduced by removal of excess dry material.

Safety and effectiveness of Arista™ AH have not been clinically evaluated in children and pregnant women. Because there have been reports of decreased amylase activity in newborns up to 10 months, absorption rates of Arista™ AH in this population may be longer than 48 hours.

Arista™ AH should be used with caution in the presence of infection or in contaminated areas of the body. If signs of infection or abscess develop where Arista™ AH has been applied, re-operation may be necessary in order to allow drainage.

Safety and effectiveness in neurosurgical and ophthalmic procedures has not been established.

Arista™ AH should not be used for controlling post-partum bleeding or menorrhagia.

PRECAUTIONS

When Arista™ AH is used in conjunction with autologous blood salvage circuits, carefully follow instructions in the Administration section of the IFU regarding proper filtration and cell washing.

Arista™ AH is intended to be used in a dry state. Contact with saline or antibiotic solutions prior to achieving hemostasis will result in loss of hemostatic potential.

Arista™ AH is not recommended for the primary treatment of coagulation disorders.

No testing has been performed on the use of Arista™ AH on bone surfaces to which prosthetic materials are to be attached with adhesives and is therefore not recommended.

Arista™ AH is supplied as a sterile product and cannot be resterilized. Unused, open containers of Arista™ AH should be discarded.

Do not apply more than 50g of Arista™ AH in diabetic patients as it has been calculated that amounts in excess of 50g could affect the glucose load.

In urological procedures, Arista™ AH should not be left in the renal pelvis or ureters to eliminate the potential foci for calculus formation.

ADVERSE REACTIONS

None of the adverse events that occurred in a randomized prospective, concurrently controlled clinical trial were judged by the Data Safety Monitoring Board to be related to the use of Arista™ AH. The most common recorded adverse events were pain related to surgery, anemia, nausea, lab values out of normal range, arrhythmia, constipation, respiratory dysfunction and hypotension – all reported in greater than 10% of the Arista™ AH treated patients. The details of this clinical trial’s adverse events can be reviewed in the IFU supplied with the product and are also available at www.bd.com.

Caution: Federal (USA) law restricts this device to sale by or on order of a licensed physician or properly licensed practitioner.

BD-14602

Sort by:

Avitene™ Microfibrillar Collagen Hemostat 5 g

Avitene™ Microfibrillar Collagen Hemostat 5g aids the process of bleeding control, adheres to irregular spaces, and is available in various sizes.

SKU/REF 1010590
Avitene™ Microfibrillar Collagen Hemostat 1 g

Avitene™ Microfibrillar Collagen Hemostat 1g aids the process of bleeding control, adheres to irregular spaces, and is available in various sizes.

SKU/REF 1010020
Avitene™ Microfibrillar Collagen Hemostat 0.5 g

Avitene™ Microfibrillar Collagen Hemostat 0.5g aids the process of bleeding control, adheres to irregular spaces, and is available in various sizes.

SKU/REF 1010010

Arista™ AH Absorbable Hemostat

Absorbable Hemostatic Particles
Hemostats

BD hemostats come in various forms that all help accelerate natural clot formation in many surgical applications. They facilitate use with features such as preloaded applicators and ready-to-use designs.
Sealants

BD sealants are designed to meet the needs of clinicians in thoracic and aortic surgery
Surgical Solutions & Products

We offer a full portfolio of surgical products

Indications:

Contraindications:

Avitene™ MCH and Avitene™ UltraFoam™ sponge should not be used in the closure of skin incisions as they may interfere with the healing of the skin edges. This is due to simple mechanical interposition of dry collagen and not to any intrinsic interference with wound healing.
It has been reported with other collagen hemostatic agents, that by filling porosities of cancellous bone, they may significantly reduce the bond strength of methylmethacrylate adhesives. Avitene™ MCH and Avitene™ UltraFoam™ sponge should not, therefore, be employed on bone surfaces to which prosthetic materials are to be attached with methylmethacrylate adhesives.

Warnings:

Avitene™ MCH and Avitene™ UltraFoam™ are inactivated by autoclaving.
Ethylene oxide reacts with bound hydrochloric acid to form ethylene chlorohydrin.
These devices have been designed for single use only. Reuse, reprocessing, resterilization or repackaging may compromise the structural integrity and/or essential material and design characteristics that are critical to the overall performance of the devices and may lead to device failure which may result in injury to the patient. Reuse, reprocessing, resterilization or repackaging may also create a risk of contamination of the device and/or cause patient infection or cross infection, including, but not limited to, the transmission of infectious diseases from one patient to another. Contamination of the devices may lead to injury, illness or death of the patient or end user. Opened, unused product should be discarded.
Moistening Avitene™ MCH or wetting with saline or thrombin impairs its hemostatic efficacy. It should be used dry.
As with any foreign substance, use of Avitene™ MCH and Avitene™ UltraFoam™ in contaminated wounds may enhance infection.
Avitene™ UltraFoam™ sponge should not be used in instances of pumping arterial hemorrhage.
Avitene™ UltraFoam™ should not be used where blood or other fluids have pooled, or in cases where the point of hemorrhage is submerged as it may mask an underlying source of bleeding, resulting in hematoma.
Avitene™ UltraFoam™ sponge will not act as a tampon or plug in a bleeding site, nor will it close off an area of blood collecting behind a tampon.
Avitene™ UltraFoam™ sponge is not intended to treat systemic coagulation disorders.
Avitene™ MCH and Avitene™ UltraFoam™ are not for injection, intraocular or intravascular use.

Adverse Reactions:

The most serious adverse reaction reported which may be related to the use of Avitene™ MCH or other collagen products are potentiation of infection including abscess formation, hematoma, wound dehiscence and mediastinitis.
Other reported adverse reactions possibly related are adhesion formation, allergic reaction, foreign body reaction and subgaleal seroma (report of a single case) and increased incidence of alveolalgia when used for packing of dental extraction sockets.
Transient laryngospasm due to aspiration of dry material has been reported following use of Avitene™ MCH in tonsillectomy.

Please consult package insert for more detailed safety information and instructions for use.

true

Our collection of literature on industries and on our offerings gives you information you can use to continue striving for excellence.

Learn more

We support the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.

Learn more

Find our training resources to help improve your clinical practices as part of our goal of advancing the world of health.

Learn More

We promote clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.

Learn more

true

Indications:

Contraindications:

Avitene™ MCH and Avitene™ UltraFoam™ sponge should not be used in the closure of skin incisions as they may interfere with the healing of the skin edges. This is due to simple mechanical interposition of dry collagen and not to any intrinsic interference with wound healing.
It has been reported with other collagen hemostatic agents, that by filling porosities of cancellous bone, they may significantly reduce the bond strength of methylmethacrylate adhesives. Avitene™ MCH and Avitene™ UltraFoam™ sponge should not, therefore, be employed on bone surfaces to which prosthetic materials are to be attached with methylmethacrylate adhesives.

Warnings:

Avitene™ MCH and Avitene™ UltraFoam™ are inactivated by autoclaving.
Ethylene oxide reacts with bound hydrochloric acid to form ethylene chlorohydrin.
These devices have been designed for single use only. Reuse, reprocessing, resterilization or repackaging may compromise the structural integrity and/or essential material and design characteristics that are critical to the overall performance of the devices and may lead to device failure which may result in injury to the patient. Reuse, reprocessing, resterilization or repackaging may also create a risk of contamination of the device and/or cause patient infection or cross infection, including, but not limited to, the transmission of infectious diseases from one patient to another. Contamination of the devices may lead to injury, illness or death of the patient or end user. Opened, unused product should be discarded.
Moistening Avitene™ MCH or wetting with saline or thrombin impairs its hemostatic efficacy. It should be used dry.
As with any foreign substance, use of Avitene™ MCH and Avitene™ UltraFoam™ in contaminated wounds may enhance infection.
Avitene™ UltraFoam™ sponge should not be used in instances of pumping arterial hemorrhage.
Avitene™ UltraFoam™ should not be used where blood or other fluids have pooled, or in cases where the point of hemorrhage is submerged as it may mask an underlying source of bleeding, resulting in hematoma.
Avitene™ UltraFoam™ sponge will not act as a tampon or plug in a bleeding site, nor will it close off an area of blood collecting behind a tampon.
Avitene™ UltraFoam™ sponge is not intended to treat systemic coagulation disorders.
Avitene™ MCH and Avitene™ UltraFoam™ are not for injection, intraocular or intravascular use.

Adverse Reactions:

The most serious adverse reaction reported which may be related to the use of Avitene™ MCH or other collagen products are potentiation of infection including abscess formation, hematoma, wound dehiscence and mediastinitis.
Other reported adverse reactions possibly related are adhesion formation, allergic reaction, foreign body reaction and subgaleal seroma (report of a single case) and increased incidence of alveolalgia when used for packing of dental extraction sockets.
Transient laryngospasm due to aspiration of dry material has been reported following use of Avitene™ MCH in tonsillectomy.

Please consult package insert for more detailed safety information and instructions for use.

true

Avitene™ Microfibrillar Collagen Hemostat is an active absorbable collagen hemostat, proven to accelerate clot formation. It effectively enhances platelet aggregation and the release of proteins to form fibrin, resulting in hemostasis.¹

Every product in the Avitene™ MCH family of hemostats is made from 100% collagen, which is proven to accelerate clot formation across surgical specialties.¹ Avitene™ also contains no thrombin and is ready to use right out of the package.¹

Avitene™ Flour: Avitene™ Flour conforms and adheres to irregular spaces, while controlling arterial bleeding.¹
Avitene™ Sheets: Avitene™ Sheets can be cut to any size and are ideal for flat surfaces or to wrap vessels and anastomosis sites.¹
Avitene™ Ultrafoam™ Collagen Sponge: This Soft, pliable sponge is ready-to-use out of the package with no soaking necessary.²

Collagen is the most abundant protein in the human body. It has a long history of safe and effective use as a biomaterial in medical technology and offers a series of advantages over synthetic biomaterials. Avitene MCH is an active collagen hemostat, whose collagen is 100% bovine and demonstrates an excellent safety profile trusted by surgeons for over 40 years.³

Avitene™ MCH is acceptable for use in all procedures where a topical hemostat is indicated. Its five versatile form factors provide an effective and simple solution for hemostasis.¹

Avitene Sheets are composed of non-woven Avitene collagen fibrils in a sheet form which may be cut into any shape or size, and is highly versatile. Avitene Sheets are commonly used in intracranial and skull base surgery, e.g. tumor removal and neurovascular surgery.¹

Avitene MCH is soft, fluffy, moldable form of microfibrillar collagen which is effective in controlling arterial hemorrhage. It conforms and adheres to irregular spaces and it’s easy to remove with gentle irrigation.¹

Avitene™ MCH adheres tightly to bloody surfaces and begins working on contact. Collagen in Avitene™ MCH activates platelets, which bind strongly and specifically aggregate and proteins release to form fibrin.¹"

Please review the Avitene Publication Summary to learn more.

Please see IFU for full products details relating to risks or complications.

Avitene™ MCH Instructions for Use
Avitene™ Ultrafoam™ Instructions for Use
Corral M, Ferko N,Hollmann S, et al. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database. Clinicoecon Outcomes Res 7, 409-421 (2015)

BD-40652

true